AM-831 drug combines muscarinic m1 partial agonism with both dopamine D2 and serotonin 5-HT2A antagonism.
The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetics of the drug candidate in healthy volunteers and to help inform the design of future studies in patients with schizophrenia.
Acadia Pharmaceuticals CEO Uli Hacksell said the preclinical studies showed that AM-831 to be the first antipsychotic drug to integrate both pro-cognitive and antipsychotic effects in schizophrenia patients.